Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Perspective on the Rx Pipeline: Diabetes and GLP-1 Agonists Situation Summary Initial therapy for individuals with T2DM who are at high risk for CVD, heart failure (HF) and/or chronic kidney disease is metformin and a glucagon-like peptide 1 (GLP-1) or sodium glucose transporter ligand 2 (SGLT-2)
Gao Y, Chen L, Du Z, Gao W, Wu Z, Liu X, et al
Med 11 , e382 (2021)
DETAILS: "Hardcore series 5 Amino 1MQ" refers to a specific peptide research chemical, 5-amino-1MQ (5-Amino-1-methylquinolinium), a selective inhibitor of the enzyme nicotinamide N-methyltransferase(NNMT)
Weight loss induced by GLP-1 medications represents an indirect but clinically relevant interaction
US$ 20.61
US$ 23.86
US$ 20.83
